Evidence map›Paper›PMID 42181181›Full record

ArticleFrontiers in endocrinology2026

A novel gain-of-function mutation (W818R) of calcium-sensing receptor in a family with autosomal dominant hypocalcemia type 1.

Min Fu, Yanxiang Luo, Kexin Xu, Lixin Guo, Qi Pan

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Min Fu *Department of Endocrinology, Beijing Hospital, National Center for Gerontology; National Clinical Research Center for Gerontology, The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Yanxiang Luo *Department of Endocrinology, Beijing Hospital, National Center for Gerontology; National Clinical Research Center for Gerontology, The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Kexin XuCenter for Human Genome Research, Key Laboratory of Molecular Biophysics of the Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China.
Lixin GuoDepartment of Endocrinology, Beijing Hospital, National Center for Gerontology; National Clinical Research Center for Gerontology, The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Qi PanDepartment of Endocrinology, Beijing Hospital, National Center for Gerontology; National Clinical Research Center for Gerontology, The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Autosomal dominant hypocalcemia type 1 (ADH1) is a rare inherited disorder caused by gain-of-function mutations in the calcium-sensing receptor ( Methods: Clinical evaluation and genetic testing were performed. Through activation of the MAPK signaling pathway,cellular functional validation was conducted to confirm the pathogenicity of this variant. Results: We report a two-generation family in which the proband presented with lifelong recurrent convulsive episodes and was misdiagnosed with epilepsy for decades, resulting in persistent symptoms despite antiepileptic therapy. His son exhibited similar manifestations. A whole-exome sequencing (WES) analysis was identified a previously unreported heterozygous Conclusion: This case highlights the critical role of genetic testing in the diagnosis of ADH1, particularly in patients with recurrent seizures or neonatal hypocalcemia with hyperphosphatemia and normal renal function. Once the diagnosis is established, treatment options for symptomatic patients include calcium supplementation and calcitriol, aiming to maintain serum calcium at the lower end of the reference range and relieve symptoms.

Indexed as

Gain of Function MutationHypercalciuriaHypocalcemiaHypoparathyroidismReceptors, Calcium-SensingAdultFemaleHumansMalePedigreeCASR protein, humanReceptors, Calcium-Sensingautosomal dominant hypocalcemiacalcium-sensing receptorgain-of-functionhypocalcemiahypoparathyroidismmutation

Identifiers

PMID42181181
PMCPMC13194590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.